Stephen Pakola's most recent trade in Regenxbio Inc was a trade of 5,267 Common Stock done at an average price of $11.2 . Disclosure was reported to the exchange on Feb. 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.16 per share. | 01 Feb 2026 | 5,267 | 253,050 (0%) | 0% | 11.2 | 58,780 | Common Stock |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 65,847 | 258,317 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 35,402 | 35,402 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.40 per share. | 02 Jan 2026 | 18,247 | 192,470 (0%) | 0% | 14.4 | 262,757 | Common Stock |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.07 per share. | 01 Feb 2025 | 5,263 | 210,717 (0%) | 0% | 8.1 | 42,472 | Common Stock |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 103,698 | 103,698 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 64,293 | 215,980 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.73 per share. | 02 Jan 2025 | 13,891 | 151,687 (0%) | 0% | 7.7 | 107,377 | Common Stock |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 58,386 | 165,578 (0%) | 0% | 0 | Common Stock |